Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Mancini

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
Leukemia Research|August 17, 2010
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemiaRoberto Latagliata, Massimo Breccia, Ida Carmosino, et al.
Blood|April 5, 2003
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresAnna Guarini, Gianluca Gaidano, Francesca Romana Mauro, et al.
Blood|May 12, 2009
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic featuresClaudia Haferlach, Cristina Mecucci, Susanne Schnittger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2009
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.
Leukemia & Lymphoma|May 23, 2015
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular responseRoberto Latagliata, Angela Romano, Marco Mancini, et al.
British Journal of Haematology|January 14, 2010
Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological studyCaterina Matteucci, Gianluca Barba, Emanuela Varasano, et al.
Acta Haematologica|December 5, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemiaRoberto Latagliata, Alessandro Isidori, Massimo Breccia, et al.
Blood|June 7, 2003
Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcomeGiuseppe Cimino, Loredana Elia, Marco Mancini, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
Leukemia Research|August 17, 2010
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemiaRoberto Latagliata, Massimo Breccia, Ida Carmosino, et al.
Blood|April 5, 2003
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresAnna Guarini, Gianluca Gaidano, Francesca Romana Mauro, et al.
Blood|May 12, 2009
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic featuresClaudia Haferlach, Cristina Mecucci, Susanne Schnittger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2009
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.
Leukemia & Lymphoma|May 23, 2015
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular responseRoberto Latagliata, Angela Romano, Marco Mancini, et al.
British Journal of Haematology|January 14, 2010
Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological studyCaterina Matteucci, Gianluca Barba, Emanuela Varasano, et al.
Acta Haematologica|December 5, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemiaRoberto Latagliata, Alessandro Isidori, Massimo Breccia, et al.
Blood|June 7, 2003
Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcomeGiuseppe Cimino, Loredana Elia, Marco Mancini, et al.
Pageof 12